Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
432 Leser
Artikel bewerten:
(2)

SHL Medical Ltd.: SHL Medical acquires 100% of the shares in Swiss company LCA Automation

SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical's response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcoming Swiss manufacturing site in Zug.

ZUG, Switzerland, July 3, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions headquartered in Zug, announced the acquisition of Swiss-based LCA Automation, a leading provider of innovative automation solutions, as well as its subsidiaries in Mexico and China, effective June 29, 2023.

SHL Medical announces the acquisition of LCA Automation effective June 29 2023

The acquisition of LCA Automation is part of SHL Medical's ongoing strategy to respond to the exponentially growing market demand, expand its global presence, and further strengthen SHL Medical's vertical capabilities globally. SHL Medical and LCA Automation have a strong track record of excellence in automation. The combination of their expertise and long-standing experience in different industries allows SHL Medical to increase its automation capacity in Europe further and leverage synergies to offer customers more efficient solutions along the value chain that include faster timelines and shorter supply chains.

Extension of strengths for customers

Acquiring LCA Automation will support SHL Medical's manufacturing operations globally, especially in providing automation expertise as well as tool maintenance and metal manufacturing for the Swiss manufacturing site that is currently under construction. This local extension of strengths in the automation field further increases high-speed and large-scale manufacturing. With the acquisition of LCA Automation, SHL is also reasserting one of its distinctive features in terms of complete in-house manufacturing. By operating as a comprehensive service provider, customers benefit from more flexibility along the whole production value chain.

"We are excited to welcome LCA Automation to the SHL family", says Ulrich Faessler, CEO of SHL Medical. "LCA Automation's expertise in automation and manufacturing solutions will complement our existing capabilities and enable us to offer a more comprehensive range of services to our customers and accelerate innovation."

Chris Rennhard, CEO of LCA Automation, adds: "SHL Medical and LCA Automation joining forces in production process technology and equipment manufacturing is a great benefit to the customers. The resulting high-level factory automation technology will enable the shortest timelines to fulfill market demands, while maintaining in-house process control and quality monitoring."

About LCA Automation

LCA Automation is a leading provider of automation solutions for industrial processes. With over 50 years of experience, LCA Automation specializes in designing and manufacturing customized solutions for our clients in a variety of industries, including automotive, electronics, and pharmaceuticals. Headquartered in Switzerland with subsidiaries in Mexico and China, LCA Automation's team of experts offers experience in designing, building, and implementing automation systems helping their customers to improve efficiency, reduce costs, and enhance their overall productivity.

About SHL Medical

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose - Enabling Patients' Independence - we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems. In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem.

Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth. For additional information, visit www.shl-medical.com

Media Contact

Carl Gillblad
Corporate Communications
Mail: info@shl-medical.com
Phone: +41 41 368 00 00

Photo - https://mma.prnewswire.com/media/2143222/SHL_Medical_LCA_Automation.jpg
Logo - https://mma.prnewswire.com/media/2143223/SHL_Medical_Logo.jpg

SHL Medical Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/shl-medical-acquires-100-of-the-shares-in-swiss-company-lca-automation-301867194.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.